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Abstract
Background: The prognosis of patients with hepatocellular carcinoma (HCC) still remains very
dismal, which is mainly due to metastasis. In our previous studies, we found that chromosome 8p
deletions might contribute to metastasis of HCC. In this study, we aimed to identify the candidate
metastatic suppressor gene on chromosome 8p.
Methods: Oligo-nucleotide microarrays which included 322 genes on human chromosome 8p
were constructed to analyze the difference in gene expression profiles between HCC tissues with
and without metastasis. The leading differentially expressed genes were identified and selected for
further analysis by real-time PCR and Western blotting. Recombinant expression plasmid vectors
for each target gene were constructed and transfected into HCC cells and its in vitro effects on
proliferation and invasion of HCC cells were also investigated.
Results: Sixteen leading differentially expressed genes were identified from the HCC tissues with
metastasis compared with those without metastasis (p < 0.01, q < 16 %). Among of the 10
significantly down-regulated genes in HCC with metastasis, methionine sulfoxide reductase A
(MSRA) had the lowest p value and false discovery rate (FDR), and was considered as a potential
candidate for metastasis suppressor gene. Real-time PCR and Western blotting confirmed that the
mRNA and protein expression levels of MSRA were significantly decreased in HCC with metastasis
compared with those without metastasis (p < 0.001), and MSRA mRNA level in HCCLM6 cells (with
high metastatic potential) was also much lower than that of other HCC cell lines. Transfection of
a recombinant expression plasmid vector and overexpression of MSRA gene could obviously inhibit
cell colony formation (4.33 ± 2.92 vs. 9.17 ± 3.38, p = 0.008) and invasion (7.40 ± 1.67 vs. 17.20 ±
2.59, p= 0.0001) of HCCLM6 cell line.
Conclusion: MSRA gene on chromosome 8p might possess metastasis suppressor activity in HCC.
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Background
Primary liver cancer (mainly hepatocellular carcinoma,
HCC) is one of the most frequent human cancers world-
wide. The number of deaths from liver cancer is very sim-
ilar to that of new cancer cases (598,000 and 626,000
respectively) and the liver cancer mortality rate is the third
highest in the world [1]. In China, liver cancer kills 54.7
people out of one-hundred-thousand per year [2].
Although many advances have been made as a result of
HCC clinical studies during the past decades that include
early detection, surgical resection and liver transplanta-
tion, the general prognosis of the patients with HCC still
remains dismal [3]. This outcome has been attributed to
the high possibility of intra-hepatic metastases and recur-
rence after curative treatment [3-6].
Cancer metastasis is a highly complex multistep process
that involves alterations in growth, dissemination, inva-
sion and survival, which leads to subsequent attachment,
angiogenesis, and growth of new cancer cell colonies [7].
Recently, the traditional metastasis paradigm has been
challenged by the observations that most of the genetic
and epigenetic changes necessary for metastasis appear to
be the hallmarks of cancer [8-10].
In our previous studies, we found that chromosome 8p
deletions might contribute to HCC metastasis [11]. This
result was further confirmed by comparisons in nude
mice models bearing human HCC with different meta-
static potentials [12]. These findings provide new locus for
exploring a new candidate metastasis suppressor of HCC.
In our recent study on two HCC cell lines with different
metastatic potentials, a novel metastatic suppressor gene,
HTPAP, was identified on chromosome 8p12 [13]. On the
basis of these findings, we aimed our current study to
compare the difference in gene expression profiles
between HCC tissues with and without metastasis, and to
identify the candidate metastatic suppressor gene on chro-
mosome 8p.
Methods
Human HCC specimens and cell lines
Human HCC tissues were obtained with informed con-
sent from 60 patients who underwent liver resection for
HCC at the Liver Cancer Institute and Zhongshan Hospi-
tal of Fudan University (Shanghai, China). These included
30 patients with metastatic HCC whose primary HCC
lesions were accompanied by intrahepatic spreading,
which had been regarded as the most frequently meta-
static site of HCC [14], in portal vein (n = 26), hepatic
vein (n = 2), or bile duct (n = 2), and 30 patients who had
only solitary HCC without metastases. All patients had a
history of hepatitis B virus (HBV) infection with an aver-
age age of 48.8 years, and 54 (90 %) of them were male.
The diagnosis and histopathological features were con-
firmed to be HCC by pathologists. The tumor sizes of pri-
mary HCCs ranged from 1 cm to 25 cm in diameter with
a median diameter of 7.8 cm.
Non-neoplastic liver tissues as references for microarrays
assays were obtained from 10 patients who also had the
history of HBV infection and underwent liver resection for
haemangioma of liver. All specimens were frozen in liq-
uid nitrogen immediately after resection and were stored
at -80°C until use.
HCC cell lines, MHCC97-L, MHCC97-H, HCCLM3 and
HCCLM6 were established from the same parent human
HCC cell line, MHCC97, in authors' institute. They have
an identical genetic background and stepwise increasing
metastatic potentials, i.e., MHCC97-L had the lowest and
HCCLM6 had the highest ability of metastasis [15,16].
They were cultured in Dulbecco's modified Eagle's
medium (DMEM) (Gibco BRL, NY, USA) supplemented
with 10 % (v/v) fetal calf serum (Hyclone, Utah, USA) at
37°C in a humidified incubator containing 5 % CO2.
This study was approved by the Ethics Committee of
Zhongshan Hospital, Fudan University (Shanghai, China)
(No. 20050310), and was in compliance with the Hel-
sinki Declaration.
RNA preparation
Total RNAs were extracted from each tissue sample and
cell line using TRIZOL reagent (Life Technologies, Grand
Island, USA) and was further purified with an RNeasy
mini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer's instructions. The quality of the total RNA
samples was determined by electrophoresis through for-
maldehyde agarose gels, and the 18S and 28S RNA bands
were visualized under ultraviolet light.
Microarrays experimental design
A reference design was used to compare the HCC with and
without metastases indirectly [17]. RNA from 10 non-
neoplastic liver tissues was pooled to generate the com-
mon reference sample. Twenty cases of HCCs with metas-
tasis and 20 HCCs without metastasis were investigated
against the common reference. Twenty metastatic HCCs
used in microarray experiments were from patients with
tumor spreading in portal vein (n = 18), hepatic vein (n =
1), or bile duct (n = 1) [see Additional file 1]. Dye swap
was performed in each comparison. Therefore, consider-
ing the two floret types, two kinds of HCCs and biological
replications, a total of 80 chips were used for comparing
the gene expression pattern between the HCCs with and
without metastasis.BMC Cancer 2007, 7:172 http://www.biomedcentral.com/1471-2407/7/172
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Description of 8p-specific microarrays
'8p-specific' microarrays were constructed using 322 genes
on human chromosome 8p based on the UniGene clus-
ters in GenBank [18]. In addition, 5 house-keeping genes
and 8 intergenic sequences from the yeast were used as
internal and external controls respectively. All of these
335 genes were spotted twice as duplicates on microar-
rays, and 6 blank spots were made as the negative con-
trols. So, total 676 spots (26 × 26 matrix) were
constructed on each '8p-specific' microarrays. Both the
design of 70-mer oligonuclearotides for each gene and the
construction of microarrays were made by CapitalBio Cor-
poration (Beijing, China).
Microarrays assays and statistic analysis
Five microgram of DNase-treated total RNA was used to
prepare fluorescent dye-labeled cDNA through Eberwine's
linear RNA amplification method followed with subse-
quent reverse transcription and Klenow enzyme reaction
according to the previously described methods [19,20].
Procedures of hybridization and washing were described
previously [20], arrays were scanned at 10-µm resolution
by using a confocal LuxScan™ scanner (CapitalBio, Bei-
jing, China), and the intensities of spots on each image
were extracted with SpotData software (CapitalBio, Bei-
jing, China). The LOWESS normalization method was
employed to normalize the logarithm transformed back-
ground corrected signal intensities within each slide,
thereafter, normalized data were median-centered for
each channel. The 4 values for each gene for each speci-
men (twice spotted) on microarrays and dye swap were
averaged as a signal intensity for each gene. Thus the dif-
ference of M (HCCs with metastases) and N (HCCs with-
out metastases) was estimated by the ln M/ref-ln N/ref
and T test were performed in SAS to compare the mean
difference between metastatic HCC and non-metastatic
HCC transcripts. In total, 322 fold change and p values
were obtained and subsequently converted to a set of q-
values using the method of Storey and Tibshirani [21].
The largest q-value in a list of genes declared to be differ-
entially expressed provides an estimate of the False Dis-
c o v e r y  R a t e  ( F D R ) ,  w h i c h  i s  u s e d  a s  a d j u s t m e n t  f o r
multiple T test.
RT-PCR
The synthesis of the first-strand cDNA was performed as
described previously [22]. Target gene fragments were co-
amplified with the internal control gene β-actin (991 bp)
respectively. For the two co-amplified genes, amplifica-
tion reaction was performed in the same tube comprising
10× PCR buffer, 25 mM MgCl2, 2 U Taq DNA polymerase
and 10 pM of each of the flanking primers. The primer
sequences were as follows: sense 5'- TGTACCAGCCA-
GAACACATG -3' and anti-sense 5'- CTGCTATCTTCACT-
CAGACC -3' for MSRA(621 bp); sense 5'-
TGGGCATGGGTCAGAAGGA -3' and anti-sense 5'- AAG-
CATTTGCGGTGGACGATGGAGG -3' for β-actin (991 bp).
The PCR profile was 7 min at 95°C followed by 26 cycles
of 30 s at 94°C, 30 s at 57°C, 45 s at 72°C, and a final
extension of 10 min at 72°C. The RT-PCR products were
determined by electrophoresis on 1.5 % agarose gel
stained with ethidium bromide.
Real-time PCR
All real-time PCR reactions were performed using a DNA
Engine Opticon Thermal Cycler (MJ Research, Waltham,
MA) and the SYBR Green PCR Core Reagents kit (Perk-
inElmer Applied Biosystems).
Regular RT-PCR was performed before real-time PCR to
determine the amplification condition to have a specific
amplification. Then real-time PCR was done in a final vol-
ume of 20 µl with 2 µl template cDNA (with a concentra-
tion of 20 ng/µl) with 10 µl Quantitect SybrGreen Kit
(Qiagen, Valencia, CA) and 20 pM of each primer for tar-
get gene and housekeeping gene(GAPDH). The primer
sequences were as follows: sense 5'-ATGCAGAAGTCGTC-
CGAGTG-3' and anti-sense 5'-TAGATGGCCGAGCGG-
TACTG-3' for MSRA  (141 bp); sense 5'-
ATGACCCCTTCATTGACC-3' and anti-sense 5'-GAAGAT-
GGTGATGGGATTTC-3' for GAPDH (131 bp).
Activation was done with HotStar Taq DNA polymerase at
95°C for 15 min, followed by 45 cycles of 94°C for 15 s,
58°C for 30 s, and 72°C for 30 s then plate read. The
Opticon Monitor Software package 1.02 was used for
detection of fluorescent signals and Tm calculations. The
transcripts of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene, a reference gene for high abundance gene
transcripts, were quantitated as the endogenous control to
normalize each test sample.
Results of real-time PCR were represented as Ct values,
where Ct was a fractional value defined as the cycle
number at which the sample fluorescent signal passes a
fixed threshold above the baseline. ∆Ct was the difference
in the Ct values derived from the specific genes being
assayed and GAPDH, the N-fold differential expression in
a specific gene of a tumor sample was expressed as 2∆Ct
[23].
Western blotting
Protein was extracted by M-PER or T-PER (Pierce, USA),
and protein concentrations were measured with the BCA
protein assay kit (Pierce, USA). Total protein (50 µg) was
separated by SDS-PAGE and transferred onto PVDF mem-
branes. After being blocked in TBST with 50 ml/L skim
milk for 2 h at room temperature, membranes were incu-
bated with the primary antibody anti-MSRA (Upstate,BMC Cancer 2007, 7:172 http://www.biomedcentral.com/1471-2407/7/172
Page 4 of 10
(page number not for citation purposes)
USA) for 2 h. Anti-GAPDH (Santa Cruz, USA) was used as
the endogenous control. The membranes were then
washed thrice with TBST solution, followed by incubation
for 1 h with HRP-linked secondary antibodies (Santa
Cruz, USA) at room temperature. Finally, the membranes
were visualized using the DAB reagent (Dako, Denmark).
Construction and transfection of the recombinant plasmid 
of MSRA gene
The full-length cDNA sequence of MSRA gene was ampli-
fied by PCR, and inserted into the BamHI and NheI sites
of the expression plasmid vector pIRES2-EGFP. Its
sequence was confirmed by DNA sequencing and the
recombinant plasmids were named pIRES2-EGFP-MSRA.
The recombinant plasmids were transfected into the
HCCLM6 cell line using Lipofectamine 2000 according to
the instructions from the manufacturer (Invitrogen, USA),
with the empty plasmid transfection as control.
Analysis of proliferation of HCC cells in vitro
Cell proliferation assays were performed by MTT
(Promega, Madison, WI) colorimetry. Twenty-four hours
after transfection, the HCC cells were treated with trypsin
and harvested, then resuspended and plated in 96-well
plates at 1 × 103 cells per well in 100 µL cell culture
medium and maintained at 37°C in a humidified incuba-
tor containing 5% CO2. After every 24 h, 10 µL of the MTT
solution was added into the triplicate wells and incubated
at 37°C for another 4 h, 100 µL of DMSO was added and
surged for 10 min to dissolve the crystal completely. Then
absorbance at 540 nm was measured to calculate the
numbers of vital cells in each well by ELISA reader.
The colony formation assay was performed to measure
growth promotion by MSRA  gene transfection into
MHCC-LM6 cells according to our previously reported
protocol [22]. Twenty-four hours after transient transfec-
tion by control (pIRES2-EGFP) and recombinant
(pIRES2-EGFP- MSRA) plasmid vectors respectively, the
transfected cells were treated with trypsin and harvested,
washed, and resuspended in fresh complete medium.
Identical numbers of empty or recombinant plasmid-
transfected cells were plated in 6-well tissue culture plates
to allow cells to form colonies. After 10 days incubation at
37°C in a humidified CO2 incubator, cells were fixed with
4% paraformaldehyde in PBS and stained with Giemsa
stain. The cut-off point for colony size was ≥ 20 cells/col-
ony. The number of colonies was counted within a field at
200× under a light microscope. For each test, a total of five
fields were selected at random, and the numbers were
averaged. The assay was repeated three times with 0.5 ×
104, 1 × 104, and 2 × 104 of the cells seeded, respectively.
In vitro Matrigel invasion assay of HCC cells
In vitro invasion assay were performed as our previously
reported protocol [22]. Briefly, 100 µL of serum-free
DMEM-diluted matrigel (0.8 mg/ml) (BD Biosciences,
San Jose, Calif., USA) was added to the Transwell fil-
ters(8.0 µM pore size; Corning, N.Y., USA) of a Boyden
chamber and incubated at 37°C for 2 h to form matrix
gels. HCCLM6 cells (1 × 105) transfected with recom-
binant plasmid vector (pIRES2-EGFP- MSRA) or pIRES2-
EGFP vector were suspended in 100 µL serum-free DMEM
and added to the top of the gels in the triplicate chambers.
A mixture of 200 µL DMEM with 10% fetal calf serum,
200 µL supernatant of HCCLM6 cell culture, and 200 µL
supernatant of NIH/3T3 cell culture was added to the
lower chamber to serve as the chemoattractant. After 48 h
of incubation at 37°C, the upper surface of the filters was
carefully wiped with a cotton-tipped applicator, and the
filters were fixed with 4% paraformaldehyde in PBS and
stained with Giemsa stain. Cells invaded across the
matrigel and passed through the Transwell filter pores
toward the lower surface of the filters, and these were
counted in five no overlapping 200× fields under a light
microscope.
Statistical analysis for real-time PCR and in vitro analysis
Statistical analyses for Real-time PCR and the in vitro
analysis were performed with software from SPSS 10.0 for
Windows (Chicago, IL., USA). Results of real-time PCR
were evaluated by Mann-Whitney tests for two independ-
ent groups. The results of the cell proliferation assay, col-
ony formation assay, and in vitro invasion assay were
evaluated by Student's t-tests. A p value < 0.05 was taken
as the level of significance.
Results
Identification of the metastasis-related genes for HCC
The '8p-specific' oligonucleotide microarrays, which were
constructed with 322 genes and ESTs on human chromo-
some 8p, were used to investigate the different transcripts
profiles between HCC with and with no metastasis. The
data of array scanning were shown in Additional file 2.
Statistical analyses, using two-group T-test based on the
normalized expression levels, were performed to deter-
mine the differentially expressed genes. Of the 322 genes
on the microarrays, 16 genes were found differentially
expressed at a level of p < 0.01 between metastatic HCC
and non-metastatic HCC, and the corresponding esti-
mated false discovery rate (FDR) for q value thresholds
was 16 % (Table 1). Among them, 10 genes were down-
regulated, including Methionine Sulfoxide Reductase A
(MSRA) as well as the other 3 well annotated genes
(WHSC1L1, ARHGEF10 and NAT1). MRSA was signifi-
cantly down-regulated (p = 0.00012, q = 3.5 %) in HCC
with metastasis compared with those without metastasis.BMC Cancer 2007, 7:172 http://www.biomedcentral.com/1471-2407/7/172
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So, it was selected for the further confirmation and func-
tional analysis.
Down-regulated expression of MSRA in metastatic HCC 
samples and cell lines
In order to confirm the results of microarrays, the mRNA
level of MSRA was examined in 40 HCC samples includ-
ing 20 primary HCCs with metastasis and 20 HCCs with-
out metastasis using real-time PCR. Twenty of them were
from those used in microarrays assays and the others were
newly selected. Since the expression level of GAPDH did
not exhibit a significant difference between HCC with and
without metastasis, it was used to normalize the MSRA
expression data. Real-time PCR results confirmed that the
expression level of MSRA  in HCC with metastasis was
obviously lower than that in HCC without metastasis (p <
0.001) (Figure 1A).
The mRNA levels of MSRA gene in MHCC97-L, MHCC97-
H, HCCLM3 and HCCLM6 cell lines were also detected by
real-time PCR. As shown in the Figure 1B, the expression
level of MSRA in HCCLM6 cells (which had the highest
metastatic ability) was significantly decreased compared
with the other cell lines. Thus, the HCCLM6 cell line was
selected for the further in vitro functional analysis of
MSRA gene.
Western blotting was carried out with 5 HCCs without
metastasis and 5 HCCs with metastasis to further confirm
the protein expression level of MSRA. Consistent with the
real-time PCR results, the protein expression level of
MSRA in HCCs with metastasis was much lower than that
in HCCs without metastasis (Figure 1C).
In vitro effect of MSRA overexpression on proliferation 
and invasion of HCC cells
To investigate the potential role of the MSRA gene on the
invasiveness of HCC cells, the recombinant expression
plasmid, named pIRES2-EGFP-MSRA, was constructed
and transfected into the HCCLM6 cell line. Empty plas-
mids were also used as a control. There was no significant
difference in the transfection efficiency between the
recombinant and empty plasmids. RT-PCR and Western
blot demonstrated that the expression levels of MSRA in
the transfected cells increased dramatically as compared
with the controls (Figure 2A).
The in vitro proliferation ability of HCCLM6 cells trans-
fected with pIRES2-EGFP-MSRA was slightly inhibited,
however, the difference did not reach statistical signifi-
cance (0.13 ± 0.03 vs. 0.14 ± 0.03, p = 0.602) (Figure 2B).
However, the ability of colony formation of HCCLM6
transfected with pIRES2-EGFP-MSRA was significantly
decreased as compared with the controls (4.33 ± 2.92 vs.
9.17 ± 3.38, p = 0.008) (Figure 2C).
In the in vitro Matrigel invasion assays, the number of cells
invaded through the transwell membrane in the pIRES2-
EGFP- MSRA transfected group (7.40 ± 1.67) (Figure 2D)
was significantly lower than those in the pIRES2-EGFP
control group (17.20 ± 2.59, p= 0.0001) (Figure 2E).
These suggested that MSRA might have the potential abil-
ity to inhibit cell invasion but have no significant effect on
the proliferation of HCC cells.
Discussion
Curative resection currently remains the major therapeu-
tic method for HCC patients. However, due to the great
possibility of tumor recurrence, caused mainly by metas-
tasis, only definitive subsets of patients have the chance of
being cured. Much like other kinds of solid malignant
tumors, HCC metastasis is a complex interacting process
between the host and cancer cells, and is regulated by
multiple genes. Understanding the genes responsible for
either enhancing or suppressing this process would allow
novel diagnostic, therapeutic and prognostic applications
Expression level of MSRA gene in the tumor tissues and cell  lines of human hepatocellular carcinoma Figure 1
Expression level of MSRA gene in the tumor tissues 
and cell lines of human hepatocellular carcinoma. A 
and B: MSRA mRNA levels of clinical specimens (T1-20 were 
HCCs without metastases, M1-20 were HCCs with metas-
tases) (A) and HCC cell lines (B) detected by real-time PCR. 
C: MSRA protein levels detected by Western blotting (T1 to 
T3, T18, and T19 were HCCs without metastasis, M14 to 
M18 were HCCs with metastasis).BMC Cancer 2007, 7:172 http://www.biomedcentral.com/1471-2407/7/172
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in evolving and improving the clinical care of HCC
In vitro effect of MSRA overexpression on the proliferation and invasion of HCC cell line Figure 2
In vitro effect of MSRA overexpression on the proliferation and invasion of HCC cell line. RT-PCR (A, upper) and 
Western blotting (A, low) showed that the expression level (both RNAs and proteins) was significantly higher in HCCLM6 
transfected with pIRES2-EGFP-MSRA (M) compared with the control that transfected with pIRES2-EGFP (P) and HCCLM6 cell 
line (LM6). There was no significant difference in proliferation of HCC cells between the MSRA-transfected group and the con-
trols (B), however, the colon formation in the recombinant vector-transfected cells were less than in the control (C). In in vitro 
matrigel invasion assay, the invasion ability of HCC cells was significantly decreased in HCCLM6 cells transfected with the 
MSRA gene (D), compared with those the transfected with empty vector (E) and the untransfected HCCLM6 cells (F).
Table 1: Differentially expressed genes between HCCs with metastases and without metastases detected by 8p-specific microarrays
Gene name GenBank number Fold change (HCC with 
metastasis/HCC without 
metastasis)
pq
MSRA NM_012331 0.55405 0.00012 0.03517
LOC203076 XM_114621.4 1.38670 0.00047 0.06824
ATP6V1B2 NM_001693 1.43027 0.00166 0.10781
ARHGEF10 NM_014629 0.54136 0.00181 0.10781
LOC392188 XM_373238 0.81971 0.00213 0.10781
LOC389651 XM_372039.1 0.65372 0.00259 0.10781
UNQ9391 NM_198464.1 1.26232 0.00287 0.10781
NAT1 NM_000662 0.71569 0.00296 0.10781
LOC92755 XM_047083.7 1.25717 0.00332 0.10781
LOC389639 XM_374258.1 0.74396 0.00371 0.10827
LOC402328 XM_378014.1 0.82349 0.00525 0.13363
UNC5D NM_080872.1 1.90792 0.00549 0.13363
TNKS NM_003747.1 1.12857 0.00709 0.15935
LOC286097 NM_181723.1 0.76227 0.00774 0.15970
LOC389624 XM_374248.1 0.68755 0.00874 0.15970
WHSC1L1 NM_023034 0.49360 0.00908 0.15970BMC Cancer 2007, 7:172 http://www.biomedcentral.com/1471-2407/7/172
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patients. It has been demonstrated that more genetic aber-
rations exist during the process of cancer progression,
invasion and metastasis [24,25]. These specific genomic
aberrations could be used for mapping tumor suppressor
genes [26], and provide clues for identifying metastasis-
related genes. Many genes, such as nm23, KAI1, KISS1,
MKK4, BrMS1 and so on, have been identified to have
relations with the tumor metastasis [27,28].
In our previous studies, we found that HCC acquired a
deletion on chromosome 8p as they progressed to meta-
static stage, and that the chromosome 8p deletion may
contribute to HCC metastasis [11]. This result was further
confirmed by comparisons in nude mice models bearing
human HCC with different metastatic potentials [12].
Using genome-wide microsatellite analysis, the deletion
on chromosome 8p was further proven to be related to
progression and metastasis of HCC, and that 8p23.3 and
8p11.2 were two regions harboring metastasis-related
genes [29]. Similar results were obtained in other groups
[30,31]. A deletion of chromosome 8p has also been
shown to play an important role in the tumor progression
and metastasis of many other kinds of human malignan-
cies besides HCC including colorectal [32,33], bladder
[34,35], breast [36], larynx [37], renal [38], and lung can-
cers [39]. Perhaps, 8p might harbor one or more tumor
suppressor genes that are important in tumor progression
and especially in the tumor metastasis of cancer including
HCC [40].
Several candidate tumor suppressor genes have been iden-
tified from 8p including DLC-1 (8p21.3-22) [41], FEZ1
(8p22) [42], liver-related putative tumor suppressor
(LTPS) gene (8p23) [43], PCM1(encoding a centrosomal
protein) and DUSP4/MKP-2  (encoding a MAP kinase
phosphatase) [44]. Alterations of these genes may occur as
an early event in the development of cancer, and their
association with metastasis is not confirmed [45] even
though one very recent study indicated that FEZ1 may
serve as a novel prognostic indicator for lung cancer [46].
It has been found that putative tumor suppressor genes
that are mapped on chromosomes 8p21-22 may be
involved in the metastasis of colorectal cancer. Allelic
losses in these regions are possible risk factors for early
lymph node metastasis [47]. Using a functional positional
cloning strategy, Nihei et al. defined the region harboring
the metastasis suppressor gene in 8p21-12, and localized
it to a 60-kb cloned region [40].
To explore the new candidate metastatic suppressor of
HCC, in our recent study on two HCC cell lines with dif-
ferent metastatic potentials, a novel metastatic suppressor
gene, HTPAP, was identified on chromosome 8p12 [13].
However, regarding the limitation of study on cell lines
and the development of human genome sequencing, in
this study, we constructed '8p specific microarrays', which
contain all of the genes and ESTs on human chromosome
8p, and used a number of clinical specimens to identify
the genes relating to the metastasis of HCC. A total of 322
genes or ESTs were found from the UniGene clusters in
GenBank and used for the construction of 8p-specific
microarrays, a different number from the previous work,
in which 100 ESTs were used [13]. Most of the functional
genes have not been completely annotated yet. Sixteen
genes were found differentially expressed between meta-
static HCC and non-metastatic HCC. Among these sixteen
genes, ten genes were down-regulated including four well-
annotated genes, MSRA, WHSC1L1, ARHGEF10 and
NAT1. Although HTPAP gene was significantly down-reg-
ulated in HCC cell line with high metastatic potentials
(data not shown), and was also down-regulated in the
metastatic HCCs, the difference did not reach the statisti-
cal criteria in this study. This suggested that there may be
differences between cell lines and clinical samples, partic-
ularly for the high-throughputs assays.
MSRA was one of the four well- annotated genes that were
significantly down-regulated in HCC with metastasis
compared with those without metastasis; therefore, it was
selected for the further confirmation and functional anal-
ysis.
The MSRA gene is located at chromosome 8p23.1. It has
been found to express ubiquitously, with highest mRNA
levels in adult kidney and cerebellum, followed by liver,
heart ventricles, bone marrow and hippocampus. How-
ever, among the fetal tissues, the highest expression level
was found in the liver [48]. In this study, both the mRNA
and protein expression levels were decreased significantly
in HCCs with metastasis. These results suggest that down-
regulation of MSRA might play a role in the progression
of HCC.
Furthermore, we investigated the effect of MSRA on the
proliferation, colony formation and invasion ability of
HCC cells in vitro. On the basis of high transfection effi-
ciency, our studies showed that MSRA  overexpression
could slightly inhibit the proliferation ability of HCCLM6
cells, and more importantly, significantly inhibit the inva-
sion ability. Although the in vivo experiments need to be
done in order to further confirm the MSRA genes func-
tions on HCC metastasis, these in vitro studies suggest that
the MSRA gene might possess metastasis suppressor activ-
ity in HCC. Also, anti-tumor activity of MSRA was seen in
a study about sulindac also[49].
Reactive oxygen can cause damage to many cellular com-
ponents via DNA base alterations, strand breaks, damag-
ing tumor suppressor genes. Secondly, oxidation also
enhances the expression of proto-oncogenes, and plays aBMC Cancer 2007, 7:172 http://www.biomedcentral.com/1471-2407/7/172
Page 8 of 10
(page number not for citation purposes)
key role in the development of human cancer. MSRA has
been implicated in protecting cells against oxidative dam-
age, which can reduce methionine sulfoxide in proteins
from oxidative damage to methionine [50]. MSRA has a
broad specificity for oxidated compounds that contain a
methyl sulfoxide group [51]. Oxidized methionine resi-
dues in different compartments are repaired by methio-
nine sulfoxide reductases of different subcellular
distribution regulated by alternative splicing [52].
The possible roles of MSRA in the development and pro-
gression of cancer are not yet fully understood. Hanbauer
et al found that calcium phospholipid-binding protein
(CPBP, synonyms: KLF6, ZF9, COPEB) can bind to the
MSRA promoter at a 39-bp sequence of its 3' end. CPBP is
a homologue of elongation factor-1 gamma, it can
enhance MSRA gene expression [53], while wild-type p53
can enhance the activity of KLF6 [54]. Abnormalities of
the p53 gene caused, by a wide range of cellular stresses
including hypoxia are the most common molecular
abnormality in human cancer, which were found in more
than 50% of malignancies [55]. MSRA may be a point
among the cyclic interconversion of MSRA, oxidation, p53
and CPBP. When oxidative damage occurs, p53, CPBP
and MSRA are down-regulated in succession. Reactive
oxygen can't be scavenged and promote the developing of
malignant tumor. However, the real association of MSRA
with oxidation, p53 and CPBP, the real mechanism of its
effect on invasion and metastasis of HCC, are not clear
yet, which deserves further study.
Conclusion
In summary, MSRA  gene, located on chromosome
8p23.1, was identified as a candidate of metastasis sup-
pressor for HCC through chromosome 8p-specific micro-
arrays analysis in HCC clinical samples. Both its mRNA
and protein levels were down-regulated significantly in
HCC with metastasis compared with HCC without metas-
tasis.  In vitro functional analyses suggested that MSRA
could suppress the invasive ability of HCC cells. And fur-
ther studies on the actual mechanisms of the effect on
invasion and metastasis of HCC are suggested.
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